Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 8Glioma 7Neoplasms 6Lymphoma 6Glioblastoma 6Breast Neoplasms 6Pancreatic Neoplasms 5Neoplasm Metastasis 5Recurrence 4Multiple Myeloma 4Melanoma 4Lymphoma, B-Cell 4Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Prostatic Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Pancreatic Ductal Adenocarcinoma 2Myelodysplastic Syndromes 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Immunoglobulin Light-chain Amyloidosis 2Carcinoma, Hepatocellular 2Carcinoma, Basal Cell 2Burkitt Lymphoma 2

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Endometrial Serous Adenocarcinoma × 30 days × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡